• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO KG PROGAV 2.0 WITH SHUNTASSISTANT 20; HYDROCEPHALUS MANAGEMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO KG PROGAV 2.0 WITH SHUNTASSISTANT 20; HYDROCEPHALUS MANAGEMENT Back to Search Results
Model Number FX413T
Medical Device Problem Code Obstruction of Flow (2423)
Health Effect - Clinical Code Hydrocephalus (3272)
Date of Event 12/23/2025
Type of Reportable Event Serious Injury
Event or Problem Description
It was reported that a progav 2.0 (#fx413t) was implanted during a procedure performed on (b)(6) 2020.According to the complainant, the shunt caused an underdrainage.The patient underwent a revision procedure on (b)(6) 2025.No patient complications were reported as a result of the revision procedure.The complained product was sent to the manufacturer for investigation.Same event/ patient as # 3004721439-2026-00012.
 
Additional Manufacturer Narrative
Visual inspection: during the investigation, scratches on the outer housing of the progav 2.0 were determined.Permeability test: a permeability test has shown that the valve is permeable.During the permeability test, bloody liquid were flushed out.Computer controlled test: to investigate the claim of under-drainage, the opening pressure is measured using a miethke computer controlled testing apparatus which simulates a cerebrospinal fluid flow.The valve is tested in the horizontal position.The results show that the valve operates within the accepted tolerances in the horizontal position.Adjustment test: the progav 2.0 was tested and is adjustable to all specified pressures.Braking force and brake function test: the brake functionality test has shown that the brake function is fully operational and the braking force is within the given tolerances.Internal inspection: after dismantling of the valve, deposits were found in progav 2.0.Result: based on our investigation results, we can determine visible deposits in the progav 2.0.The deposits did not affect the technical properties at the time of the investigation.At the time of the investigation, we are unable to determine how the aforementioned functional impairment occurred.Organic material in the patient's own cerebrospinal fluid may have temporarily affected the function and is a known side effect of hydrocephalus therapy.Not every deposit in a shunt system, depending on its location, quantity, and consistency, leads to a deterioration in properties.The examination of the returned item is complete with the creation of this report.We can exclude a defect at the time of release.The valve met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.No further regulatory actions are required from our point of view.Transcribed.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROGAV 2.0 WITH SHUNTASSISTANT 20
Common Device Name
HYDROCEPHALUS MANAGEMENT
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM  14469
Manufacturer (Section G)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM   14469
Manufacturer Contact
joerg knebel
ulanenweg 2
potsdam, 14469
GM   14469
MDR Report Key24114902
Report Number3004721439-2026-00013
Device Sequence Number20318589
Product Code JXG
UDI-Device Identifier04041906136550
UDI-Public(01)04041906136550(17)230325(10)20037212
Combination Product (Y/N)N
Initial Reporter CountryGM
PMA/510(K) Number
K161853
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2020
Device Explanted Year2025
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Foreign,User Facility,Company Representative
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date (Section B) 01/20/2026
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date03/25/2023
Device Model NumberFX413T
Device Catalogue NumberFX413T
Device Lot Number20037212
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer01/05/2026
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 01/05/2026
Initial Report FDA Received Date01/20/2026
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured03/26/2018
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age27 YR
Patient SexFemale
Patient Weight70 KG
-
-